373110 — Xcell Therapeutics Balance Sheet
0.000.00%
- KR₩41bn
- KR₩38bn
- KR₩2bn
Annual balance sheet for Xcell Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Equivalents | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 14,632 | 5,556 | 1,359 | 8,802 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 273 | 648 | 623 | 920 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 15,425 | 7,216 | 4,421 | 10,512 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 7,515 | 7,372 | 5,355 | 4,472 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Long Term Notes Receivable | ||||
Other Long Term Assets | ||||
Total Assets | 23,702 | 15,509 | 10,468 | 16,890 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 5,258 | 5,187 | 5,443 | 4,906 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Funded Status | ||||
Total Liabilities | 7,477 | 7,026 | 8,085 | 7,769 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
ESOP Debt Guarantee | ||||
Other Equity | ||||
Total Equity | 16,225 | 8,483 | 2,384 | 9,121 |
Total Liabilities & Shareholders' Equity | 23,702 | 15,509 | 10,468 | 16,890 |
Total Common Shares Outstanding |